Evaluation of Plasma Urokinase –Type Plasminogen Activator Receptor and Interleukin 34 in Patients with Chronic Hepatitis C as Serological Fibrosis Markers

Abstract

Background: Hepatitis C virus (HCV) infection is a progressive disease that may result in chronic hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Assessment of liver fibrosis is essential factor in the management of chronic HCV. Objective: to evaluate plasma soluble urokinase plasminogen activator receptor (sUPAR) and interleukin-34 (IL-34) as serological markers of liver fibrosis in patients with chronic HCV. Methods: This case-control study enrolled 60 chronic HCV patients who were subdivided into three groups of mild, moderate and severe hepatic fibrosis depending on fibrosis-4 score (FIB-4). Patients were compared with 20 age and sex matched controls. Plasma sUPAR and IL-34 levels were measured by enzyme linked immunosorbent assay (ELISA). Results: Plasma sUPAR and IL-34 were significantly increased in HCV patients when compared with controls, and their increase was positively correlated with progression of hepatic fibrosis. Plasma sUPAR and IL-34 positively correlated with serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT), and negatively correlated with hemoglobin concentration and platelet count. The output data of ROC curve to differentiate patients from controls revealed that sUPAR at cut-off >186.2 ng/L and AUC of 0.944 had (85%) sensitivity and (100%) specificity, and IL-34 at cut off > 16.4 ng/L and AUC of 0.942 had (75%) sensitivity and (100%) specificity. While IL-34 at cut off > 55.3ng/L and AUC of 0.844 had (85%) sensitivity and (80%) specificity. Conclusions: Increased plasma levels of sUPAR and IL-34 in chronic HCV patients with liver fibrosis and their increase was parallel to the degree of liver fibrosis. Plasma sUPAR and IL-34 can be used as serological markers of liver fibrosis in chronic HCV patients.